HomeStock ScreenerMangalam Drugs & Organics

Mangalam Drugs & Organics Share Price | Mangalam Drugs & Organics Stock Screener

MANGALAM Pharmaceuticals
Share Price NSE
₹28.09
▼ -0.16 (-0.57%)
2026-07-03 00:00:00
Share Price BSE
₹28.39
▲ 0.19 (0.67%)
2026-07-03 00:00:00
As of July 3, 2026, the Mangalam Drugs & Organics share price (NSE: MANGALAM) is ₹28.09 on NSE and ₹28.39 on BSE, down 0.57% from the previous close, with shares trading between ₹27.61 and ₹29.30, and a 52-week range of ₹23.78–₹92.46. Analyse MANGALAM price trends and track historical price performance. Use the Mangalam Drugs & Organics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Mangalam Drugs & Organics Market Cap ₹44.86 Cr.
MANGALAM P/E Ratio (TTM) -1.02
Mangalam Drugs & Organics P/B Ratio 0.47
EPS (TTM) ₹-28.05
Dividend Yield -
Debt to Equity 0.73
MANGALAM 52 Week High ₹92.46
Mangalam Drugs & Organics 52 Week Low ₹23.78
Operating Margin -8.00%
Profit Margin -19.40%
MANGALAM Revenue (TTM) ₹67.00
EBITDA ₹-6.00
Net Income ₹-13.00
Total Assets ₹315.00
Total Equity ₹103.00

Mangalam Drugs & Organics Share Price Chart

Screen Mangalam Drugs & Organics share price with an interactive chart. Analyse MANGALAM price trends and volatility across different timeframes.

Mangalam Drugs & Organics Company Profile - Fundamental Screener

Screen Mangalam Drugs & Organics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MANGALAM shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE584F01014

Mangalam Drugs & Organics Balance Sheet Screener

Screen MANGALAM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024
Assets
Total Assets 315 366 334
Current Assets 156 199 176
Fixed Assets 159 163 148
Liabilities
Total Liabilities 0 0 0
Current Liabilities 15 26 34
Non-Current Liabilities 0 0 0
Shareholders' Equity
Total Equity 103 149 136
Share Capital 16 16 16
Reserves & Surplus 87 133 120

Mangalam Drugs & Organics Income Statement Screener - Profit & Revenue Analysis

Screen Mangalam Drugs & Organics income statement and profit fundamentals. Analyze MANGALAM quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Mangalam Drugs & Organics share price evaluation.
Item 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec
Revenue 67 59 49 57 73 89 80 77 102 97
Expenses 73 60 52 62 63 80 71 68 91 90
EBITDA -6 -1 -3 -5 10 9 9 8 12 7
Operating Profit % -8.00% -3.00% -6.00% -8.00% 14.00% 10.00% 11.00% 11.00% 11.00% 7.00%
Depreciation 5 5 5 5 5 4 4 4 4 4
Interest 3 4 5 4 4 4 4 4 4 3
Profit Before Tax -13 -10 -13 -13 2 1 1 1 4 0
Tax 0 0 -5 1 2 0 -2 -2 0 -1
Net Profit -13 -10 -7 -14 0 1 3 3 4 1
EPS -8.48 -6.21 -4.64 -8.72 0.04 0.81 1.70 1.70 2.23 0.31

Mangalam Drugs & Organics Cash Flow Screener - Liquidity Fundamentals

Screen MANGALAM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March
Operating Activities 43 4
Investing Activities -20 -12
Financing Activities -22 5
Net Cash Flow 1 -3

Mangalam Drugs & Organics Shareholding Pattern Screener

See Mangalam Drugs & Organics shareholding pattern with promoter, FII, and DII holdings. Check Mangalam Drugs & Organics promoter holding and ownership changes for MANGALAM on TickJournal.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept
Promoter Holding 35.65% 50.30% 50.30% 50.30% 35.64% 50.32% 50.32% 50.30%
FII Holding 0.32% 0.47% 0.53% 0.11% 0.13% 0.26% 0.21% 0.11%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 60.14% 44.55% 44.53% 45.00% 57.52% 44.22% 44.70% 44.91%
Other Holding 3.89% 4.68% 4.63% 4.59% 6.70% 5.20% 4.77% 4.67%
Shareholder Count 25,140 19,697 19,728 19,881 21,227 19,173 19,312 19,508

Mangalam Drugs & Organics Share Dividend Screener - Share Yield Analysis

Check Mangalam Drugs & Organics dividend history with payout and yield data. View Mangalam Drugs & Organics dividend details including ex-dates and amounts for MANGALAM stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.50 0.92%
2017-March ₹0.00 0.00%

Mangalam Drugs & Organics Stock Index Membership

See which indices include Mangalam Drugs & Organics stock. Check MANGALAM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Mangalam Drugs & Organics is not part of any tracked indices.
Only major market indices are tracked in our system.

Mangalam Drugs & Organics Market Events Screener - Corporate Actions

Get Mangalam Drugs & Organics corporate actions including splits, bonuses, and buybacks. Check Mangalam Drugs & Organics stock events that may affect MANGALAM share price.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA -7.92%
Annual General Meeting NA -4.57%
2026-05-14 2026-05-14 Quarterly Result Announcement NA 3.97%
2026-01-15 2026-01-15 Quarterly Result Announcement NA 33.96%
2025-11-20 2025-11-20 Quarterly Result Announcement NA -17.31%
2025-08-12 2025-08-12 Extraordinary General Meeting NA -9.85%
2025-08-07 2025-08-07 Quarterly Result Announcement NA -4.03%
2025-05-17 2025-05-17 Quarterly Result Announcement NA 4.63%
2025-02-13 2025-02-13 Quarterly Result Announcement NA 1.61%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -4.83%

Mangalam Drugs & Organics Competitors Screener - Peer Comparison

Screen MANGALAM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 449,827 38.82 58,220 6.38% 11,565 65.03
Divis Laboratories 174,081 69.38 10,560 8.73% 2,520 43.32
Torrent Pharmaceuticals 157,634 71.51 13,886 20.34% 2,138 66.05
Cipla 117,459 30.13 29,045 2.24% 3,870 68.02
Dr Reddys Laboratories 114,822 27.10 33,593 -0.44% 3,998 73.77
Zydus Life Science 112,829 21.63 26,720 13.65% 5,242 66.06
Lupin 110,115 20.00 27,488 19.98% 5,345 66.98
Mankind Pharma 102,623 52.44 14,278 12.03% 1,750 59.48
Aurobindo Pharma 89,879 25.78 33,385 3.21% 3,376 65.10
Laurus Labs 80,995 88.02 6,868 22.01% 890 70.64

Mangalam Drugs & Organics Company Announcements - News Screener

Screen MANGALAM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-07-03 Closure of Trading Window -
2026-06-18 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-06-18 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-06-17 Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure -
2026-05-25 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-25 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-19 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-18 Dispatch Of Postal Ballot Notice Dated 18.05.2026 By Way Of Remote E- Voting For Taking Shareholders Approval For Reappointment Of Shri Praveen Saxena (Independent Director DIN: 03199264) For Second Term Of 5 Consecutive Years -
2026-05-16 Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure -
2026-05-15 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-14 Approval Of Audited Financial Results For The Quarter Ended 31St March 2026 -
2026-05-14 Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th May 2026 For Declaration Of Audited Financial Results(Standalone & Consolidated) Of The Company For The Quarter And Year Ended 31St March 2026 -
2026-05-06 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 14Th May 2026 Inter-Alia To Approve Audited Financial Results(Standalone & Consolidated) Of The Company For The Period Ended 31St March 2026 -
2026-04-29 Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-04-29 Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-04-29 Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-04-17 Announcement under Regulation 30 (LODR)-Change in Management -
2026-04-17 Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer -
2026-04-16 Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure -
2026-04-10 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -